Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Inclusion Criteria:

≥ 16 years of age at the time of obtaining informed consent
Eastern Cooperative Oncology Group performance status of 0 or 1 at screening
At least one PET-avid measurable lesion according to Modified Lugano Criteria after the last line of therapy.
Confirmed histological diagnosis of active relapse/refractory cHL
Failed at least 2 prior lines of systemic therapy.
No previous treatment with anti-TIM-3.
Adequate organ and bone marrow function
Non-pregnant women and willingness of female patients to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
Minimum body weight ≥ 40 kg for all participants.

Exclusion Criteria:

Unresolved toxicities of ≥ Grade 2 from prior therapy
Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy
Patients with CNS involvement or leptomeningeal disease.
History of organ transplantation (e.g., stem cell or solid organ transplant).
Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose of study intervention.
Active infection including TB, HIV, hepatitis A, chronic or active hepatitis B, chronic or active hepatitis C, active COVID-19 infection
History of arrhythmia which is requires treatment, symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia
Uncontrolled intercurrent illness.
Active or prior documented pathologically confirmed autoimmune or inflammatory disorders.
Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid treatment, or any evidence of clinically active ILD
Other invasive malignancy within 2 years prior to screening
Congenital long QT syndrome or history of QT prolongation associated with other medications that cannot be changed or discontinued based on a cardiologist assessment
Current or prior use of immunosuppressive medication within 14 days prior to the first dose of study intervention
Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.